Transcription factor switching drives subtype-specific pancreatic cancer

Shalini V., Rao, Lisa, Young, Danya, Cheeseman, Sean, Flynn, Niklas, Krebs, Dominique Laurent, Couturier, Stephanie, Mack, Rebecca, Brais, Jill, Temple, Amy, Smith, Evangelia, Papachristou, Catarina, Pelicano, Chandra Sekhar Reddy, Chilamakuri, Krzysztof, Herka, Hideo, Baba, Luay, Farah, Phyllis F., Cheung, Jens, Siveke, Stéphane, Guerrier, Luca, Insolia, Michael, Gill, Emily, Archer Goode, Steven, Kupczak, Yi, Cheng, Giacomo, Borsari, Duncan, Jodrell, Clive, D’Santos, Alasdair, Russell, Barbara T., Grünwald, Eva, Serrao, Igor, Chernukhin, Jason S., Carroll

Nature Genetics |

Emerging evidence suggests that lineage-specifying transcription factors control the progression of pancreatic ductal adenocarcinoma (PDAC). We have discovered a transcription factor switching mechanism involving the poorly characterized orphan nuclear receptor HNF4G and the putative pioneer factor FOXA1, which drives PDAC progression. Using our unbiased protein interactome discovery approach, we identified HNF4A and HNF4G as reproducible, FOXA1-associated proteins, in both preclinical models and Whipple surgical samples. In the primary tumor context, we consistently find that the dominant transcription factor is HNF4G, where it functions as the driver. A molecular switch occurs in advanced disease, whereby HNF4G expression or activity decreases, unmasking FOXA1’s transcriptional potential. Derepressed FOXA1 drives late-stage disease by orchestrating metastasis-specific enhancer–promoter loops to regulate the expression of metastatic genes. Overall survival is influenced by HNF4G and FOXA1 activity in primary tumor growth and in metastasis, respectively. We suggest that the existence of stage-dependent transcription factor activity, triggered by molecular compartmentalization, mediates the progression of PDAC.